 | Up a level |
2022
Wolf, J., Garon, B. E., Groen, M. H. J., Tan, W. D. S., Robeva, A., Le Mouhaer, S., Carbini, M., Chassot-Agostinho, A. and Heist, S. R. (2022). Capmatinib in MET exon 14-mutated advanced NSCLC: updated results from the GEOMETRY mono-1 study. Pneumologie, 76. S. S39 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
Wolf, J., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Robeva, A., Le Mouhaer, S., Carbini, M., Yovine, A. and Heist, R. (2022). Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Ann. Oncol., 33. S. S42 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Heist, R. S., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Tanriverdi, O., Robeva, A., Le Mouhaer, S., Carbini, M., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial. Ann. Oncol., 32. S. S986 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Souquet, P-J., Kim, S-W., Solomon, B., Vansteenkiste, J. F., Carbini, M., Jary, A., Glaser, S., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study. Ann. Oncol., 32. S. S1033 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041